Ami organics

Surat, India Founded: 2007 • Age: 19 yrs Listed
Advanced API intermediates are manufactured for pharmaceutical use.

About Ami organics

Ami organics is a publicly listed company based in Surat (India) founded in 2007. Advanced API intermediates are manufactured for pharmaceutical use. The company has 244 employees. Ami organics has completed 1 acquisition, including Baba Fine Chemicals. Its Indian entity Acutaas Chemicals Limited reported revenue of ₹1,381 Cr. Ami organics offers products and services including Pharmaceutical Intermediates, Speciality Chemicals, Make to Order Products, and Paraben Formulations. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and API Production. Its competitors include Viyash, Inventys and Blue Jet Healthcare; 2 of its 3 listed competitors have raised funding.

Company details

Founded in 2007 and based in Surat, India, Ami Organics operates in the pharmaceutical sector. Advanced intermediates for APIs and new chemical entities are produced, with clinical and commercial services provided. Certifications held include GMP, ISO 9001:2008, ISO 14001:2004, OHSAS 18001:2007, and SA 8000:2008. Memberships are maintained with Common Effluent Treatment Plant and Toxic Solid Disposal Site facilities.

  • Headquarters Surat, India
  • Employees 244
  • Stage Public
  • Sectors
    Healthcare
  • Email
    ••••••••
  • Phone
    •••• ••••
  • Website amiorganics.com
  • Social X Facebook
  • Legal Name Acutaas Chemicals Ltd
Key Metrics
  • Market Cap
    ₹32,561 Cr

    ACUTAAS · NSE

  • Share Price
    ₹3,833.50

    -3.61% today

  • Revenue
    ₹1,339 Cr

    FY 2025-26 · +33.0% YoY

  • EBITDA
    ₹480 Cr

    Margin 35.9%

  • Net Profit
    ₹356 Cr

    FY 2025-26 · +124.5% YoY

  • P/E (TTM)
    74.4x

    P/B 17.6x

  • ROE
    24.1%

    ROCE 32.2%

  • Debt / Equity
    0.02

    Interest cover 0.7x

  • Employee Count
    244
  • Investments & Acquisitions

Products & Services of Ami organics

Ami organics offers a comprehensive portfolio of products and services, including Pharmaceutical Intermediates, Speciality Chemicals, Make to Order Products, and Paraben Formulations.

Pharmaceutical Intermediates
Chemical Products

Intermediates used in pharmaceutical manufacturing processes.

Speciality Chemicals
Chemical Products

Advanced chemicals for specialized industrial applications.

Make to Order Products
Custom Manufacturing

Tailored chemical solutions based on client specifications.

Paraben Formulations
Chemical Formulations

Formulated chemicals for preservation in various sectors.

Board of directors of Acutaas Chemicals Limited (Ami organics)

Acutaas Chemicals Limited is the primary company behind Ami organics. The boards of the 2 registered companies of Ami organics currently have 8 directors; the longest-serving is Nareshkumar Ramjibhai Patel, appointed in 2007. 11 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Nareshkumar Ramjibhai Patel
DIN 00906232
Managing Director12 Jun 200719 yrs 5 moAcutaas Chemicals Limited, Ami Procure Private Limited
Chetankumar Chhaganlal Vaghasia
DIN 01375540
Whole-time director12 Jun 200719 yrs 5 moAcutaas Chemicals Limited, Ami Procure Private Limited
Girikrishna Maniar
DIN 07515981
Director23 Apr 20188 yrs 6 moAcutaas Chemicals Limited
Virendra Nath Mishra
DIN 07815490
Whole-time director03 Mar 20215 yrs 8 moAcutaas Chemicals Limited
Richa Manoj Goyal
DIN 00159889
Director01 Apr 20215 yrs 7 moAcutaas Chemicals Limited
Hetal Madhukant Gandhi
DIN 00106895
Director28 Apr 20215 yrs 6 moAcutaas Chemicals Limited
Ram Mohan Lokhande
DIN 08117035
Whole-time director08 Feb 20224 yrs 9 moAcutaas Chemicals Limited
Anita Bandyopadhyay
DIN 08672071
Director08 Feb 20224 yrs 9 moAcutaas Chemicals Limited

People of Ami organics

6 people are tracked at Ami organics (2 in leadership, 4 in team); the tracked headcount is 244.

NameRoleGroup
Managing DirectorLeadership
President & Board Of Director - OperationsLeadership
Badrish Patel
Senior Executive EHSTeam
Dhaval Dobariya
Manager EHSTeam
Satish Revankar
IT Hod/ CIOTeam
Dharmesh Pipala
Jr. OfficerTeam
Premium access

Complete people profiles for Ami organics

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Ami organics

Ami organics is a publicly listed company on the NSE with ticker symbol ACUTAAS in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date14 Sep 2021
  • Listed onBSE: 543349 · NSE: AMIORG
  • Listed entityAcutaas Chemicals Ltd
  • Exchange sectorHealth technology
  • ISININE00FF01025
  • Share price₹3,160.50 (-0.51% on the day) · 2026-10-14
  • Market capitalisation₹26,067 Cr
  • Price to earnings67.2
  • EPS (diluted, trailing year)₹47.00
  • Dividend yield0.08%
  • Volume (last session)347,242

Financials of Ami organics

Exchange-reported figures of Acutaas Chemicals Limited, the listed company behind Ami organics (NSE: ACUTAAS).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹1,339 Cr
+33.0% YoY
EBITDA
₹480 Cr
+107.0% YoY
Profit After Tax
₹356 Cr
+124.5% YoY
Net Worth
₹1,654 Cr
+26.3% YoY
Total Assets
₹1,751 Cr
+31.1% YoY
Total Debt
₹35.60 Cr
+175.3% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue1,3391,007717617520341240
Revenue growth+33.0%+40.3%+16.3%+18.6%+52.7%+42.1%-
EBITDA48023296.4012310580.1641.00
EBITDA margin+35.9%+23.1%+13.4%+19.9%+20.2%+23.5%+17.1%
Profit before tax48321681.8911291.4571.7334.73
Net profit35615961.7183.8571.9554.1428.05
Net profit margin+26.6%+15.8%+8.6%+13.6%+13.8%+15.9%+11.7%
EPS (₹)43.5119.3911.6022.8619.7517.1426.16
Balance sheet
Total assets1,7511,336901598524308174
Net worth1,6541,310674594522167112
Total debt35.6012.932173.600.8413759.42
Cash & bank22524953.3158.6799.552.683.82
Net working capital67759831429730011465.93
Cash flow
Cash from operations29211812565.53(11.93)27.9627.08
Cash from investing(266)(224)(365)(33.04)(121)(101)(23.94)
Cash from financing4.10261239(12.25)14072.110.19
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue437330433393306207308275
Revenue growth (YoY)+42.7%+59.1%+40.3%+43.0%+24.1%+17.3%--
Other income5.101.8011.114.709.8415.945.781.67
EBITDA17611318415195.3350.9184.9568.67
EBITDA margin+40.3%+34.3%+42.4%+38.3%+31.1%+24.6%+27.5%+25.0%
Depreciation12.699.829.639.828.408.137.306.32
Interest1.021.141.190.860.580.640.600.69
Profit before tax16710418414596.1958.0882.8363.33
Tax44.2228.9249.5238.4424.3214.0720.1217.89
Net profit12374.9913410671.8744.0162.7145.44
EPS (₹)15.249.0416.0413.108.825.417.8011.35
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue1,324990688617520341240
Revenue growth+33.7%+44.0%+11.5%+18.6%+52.7%+42.1%-
EBITDA48322575.9012310580.2141.10
EBITDA margin+36.5%+22.8%+11.0%+19.9%+20.2%+23.6%+17.2%
Profit before tax49321469.1111291.4571.7334.76
Net profit36415759.0483.9172.0554.6228.16
Net profit margin+27.5%+15.9%+8.6%+13.6%+13.9%+16.0%+11.8%
EPS (₹)44.7319.4911.8422.8719.7517.1426.16
Balance sheet
Total assets1,7051,325879591519305170
Net worth1,6681,312675587518164108
Total debt32.0311.102033.360.8413759.42
Cash & bank16524131.9458.6198.921.563.27
Net working capital60958128929529811161.51
Cash flow
Cash from operations30511610155.73(9.69)26.3827.25
Cash from investing(334)(234)(337)(20.47)(122)(100)(24.48)
Cash from financing3.68274235(14.44)14072.110.19
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue433322422391305206304271
Revenue growth (YoY)+41.9%+56.5%+38.7%+44.3%+25.3%+20.4%--
Other income8.054.4814.556.348.9716.025.692.17
Total expenses250213241237209155220204
EBITDA18311018115496.6050.9984.0666.65
EBITDA margin+42.3%+34.0%+43.0%+39.5%+31.7%+24.8%+27.6%+24.6%
Depreciation9.319.028.839.027.727.466.565.67
Interest0.991.121.070.810.570.620.380.61
Profit before tax18110418615197.2858.9382.8162.54
Tax45.3528.1248.7939.1424.3914.2819.9717.24

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 20 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue437330433393306207308275
Revenue growth (YoY)+42.7%+59.1%+40.3%+43.0%+24.1%+17.3%--
Other income5.101.8011.114.709.8415.945.781.67
EBITDA17611318415195.3350.9184.9568.67
EBITDA margin+40.3%+34.3%+42.4%+38.3%+31.1%+24.6%+27.5%+25.0%
Depreciation12.699.829.639.828.408.137.306.32
Interest1.021.141.190.860.580.640.600.69
Profit before tax16710418414596.1958.0882.8363.33
Tax44.2228.9249.5238.4424.3214.0720.1217.89
Net profit12374.9913410671.8744.0162.7145.44
EPS (₹)15.249.0416.0413.108.825.417.8011.35
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue1,3391,007717617520341240
Revenue growth+33.0%+40.3%+16.3%+18.6%+52.7%+42.1%-
Other income41.5916.937.494.322.761.382.84
Total expenses859775621494415260199
Employee cost11883.6663.1148.8441.3721.0112.95
EBITDA48023296.4012310580.1641.00
EBITDA margin+35.9%+23.1%+13.4%+19.9%+20.2%+23.5%+17.1%
Depreciation35.9926.6216.0612.3410.084.193.52
Interest3.276.225.942.416.415.625.59
Profit before tax48321681.8911291.4571.7334.73
Tax12655.7533.2028.8819.5017.727.29
Net profit35615961.7183.8571.9554.1428.05
Net profit margin+26.6%+15.8%+8.6%+13.6%+13.8%+15.9%+11.7%
EPS (₹)43.5119.3911.6022.8619.7517.1426.16
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital40.9440.9336.8836.4436.4431.5010.50
Reserves & surplus1,6131,269637558486135101
Shareholders' funds (net worth)1,6541,310674594522167112
Minority interest57.1910.458.760.000.000.000.00
Secured loans17.448.182173.600.8410846.51
Unsecured loans18.164.750.000.000.0028.2812.91
Total debt35.6012.932173.600.8413759.42
Total liabilities1,7511,336901598524308174
Assets
Gross block86265249829823120397.78
Net block74557042725920518685.19
Capital work in progress33213012529.802.960.2011.71
Investments0.200.200.201.651.711.431.73
Inventories23118015711911260.3652.34
Sundry debtors36329020623016412156.40
Cash & bank balances22524953.3158.6799.552.683.82
Loans & advances62.5572.2779.4249.0254.1532.498.47
Total current assets881792496457430216121
Total current liabilities20419418216012910255.10
Net working capital67759831429730011465.93
Total assets1,7511,336901598524308174
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash18529.7030.5310.302.683.820.50
Net cash from operating activities29211812565.53(11.93)27.9627.08
Net cash from investing activities(266)(224)(365)(33.04)(121)(101)(23.94)
Net cash from financing activities4.10261239(12.25)14072.110.19
Net change in cash30.33156(0.83)20.247.61(1.14)3.33
Closing cash22524953.3158.6799.552.683.82
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+33.0%+40.3%+16.3%+18.6%+52.7%+42.1%-
EBITDA growth+107.0%+140.7%-21.4%+16.6%+31.2%+95.5%-
PBT growth+123.3%+164.0%-27.0%+22.7%+27.5%+106.5%-1.1%
Net income growth+124.5%+157.2%-26.4%+16.5%+32.9%+93.0%-
Revenue CAGR (3Y)+29.5%+24.6%+28.2%+37.0%+29.7%+21.9%+14.4%
EBITDA CAGR (3Y)+57.7%+30.2%+6.3%+44.1%+35.7%+38.0%+21.0%
Profitability & leverage
Net income margin+26.6%+15.9%+6.8%+13.5%+13.8%+15.9%+11.5%
Return on capital employed+32.2%+20.1%+16.1%+20.4%+23.5%+32.1%+26.0%
Return on net worth+24.1%+16.2%+10.7%+14.9%+20.9%+38.8%+28.3%
Debt / equity0.020.120.170.000.200.700.58
Long-term debt / equity0.000.060.090.000.110.330.22
Interest cover0.743.037.392.196.747.4014.91
Efficiency & per share
Fixed asset turnover1.771.751.802.332.402.272.54
Inventory turnover6.515.985.205.336.036.045.27
Debtors turnover4.104.053.293.133.663.853.62
EPS (₹)43.5119.3911.6022.8619.7517.1426.16
Dividend per share (₹)2.501.503.003.003.000.000.00
Book value per share (₹)201.97159.97182.75163.01143.3452.99106.49
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue433322422391305206304271
Revenue growth (YoY)+41.9%+56.5%+38.7%+44.3%+25.3%+20.4%--
Other income8.054.4814.556.348.9716.025.692.17
Total expenses250213241237209155220204
EBITDA18311018115496.6050.9984.0666.65
EBITDA margin+42.3%+34.0%+43.0%+39.5%+31.7%+24.8%+27.6%+24.6%
Depreciation9.319.028.839.027.727.466.565.67
Interest0.991.121.070.810.570.620.380.61
Profit before tax18110418615197.2858.9382.8162.54
Tax45.3528.1248.7939.1424.3914.2819.9717.24
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue1,324990688617520341240
Revenue growth+33.7%+44.0%+11.5%+18.6%+52.7%+42.1%-
Other income45.8818.3413.794.322.761.332.77
Total expenses841765612494415260199
Employee cost11180.9560.9248.8441.3720.9912.77
EBITDA48322575.9012310580.2141.10
EBITDA margin+36.5%+22.8%+11.0%+19.9%+20.2%+23.6%+17.2%
Depreciation33.0324.0514.6912.3410.084.193.52
Interest3.085.865.892.416.415.625.59
Profit before tax49321469.1111291.4571.7334.76
Tax12754.0325.4228.8819.5017.727.29
Net profit36415759.0483.9172.0554.6228.16
Net profit margin+27.5%+15.9%+8.6%+13.6%+13.9%+16.0%+11.8%
EPS (₹)44.7319.4911.8422.8719.7517.1426.16
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital40.9440.9336.8836.4436.4431.5010.50
Reserves & surplus1,6271,27163855048213297.48
Shareholders' funds (net worth)1,6681,312675587518164108
Secured loans0.000.002033.360.8410846.51
Unsecured loans32.0311.100.000.000.0028.2812.91
Total debt32.0311.102033.360.8413759.42
Total liabilities1,7051,325879591519305170
Assets
Gross block71157741026120417774.77
Net block60149935722217816162.18
Capital work in progress22813012529.802.960.2011.71
Investments11867.7367.7333.4533.4033.2427.89
Inventories22717415111911260.3652.34
Sundry debtors36028921323016211952.51
Cash & bank balances16524131.9458.6198.921.563.27
Loans & advances57.1069.4471.9046.6753.9632.498.47
Total current assets809773468455427213117
Total current liabilities20019317916012910255.08
Net working capital60958128929529811161.51
Total assets1,7051,325879591519305170
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash18529.4930.489.661.563.270.32
Net cash from operating activities30511610155.73(9.69)26.3827.25
Net cash from investing activities(334)(234)(337)(20.47)(122)(100)(24.48)
Net cash from financing activities3.68274235(14.44)14072.110.19
Net change in cash(24.57)155(0.99)20.828.10(1.72)2.96
Closing cash16524131.9458.6198.921.563.27
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+33.7%+44.0%+11.5%+18.6%+52.7%+42.1%-
EBITDA growth+114.5%+196.6%-38.1%+16.6%+31.1%+95.2%-
PBT growth+130.7%+209.0%-38.4%+22.7%+27.5%+106.4%-5.0%
Net income growth+131.9%+165.8%-29.6%+16.5%+31.9%+94.0%-
Revenue CAGR (3Y)+29.0%+23.9%+26.4%+37.0%+30.2%+21.9%+14.4%
EBITDA CAGR (3Y)+57.9%+28.9%-1.8%+44.0%+35.0%+38.0%+21.1%
Profitability & leverage
Net income margin+27.7%+16.1%+6.4%+13.5%+13.8%+15.9%+11.5%
Return on capital employed+32.7%+19.9%+13.5%+20.7%+23.8%+32.6%+26.4%
Return on net worth+24.6%+16.1%+9.4%+15.1%+21.1%+39.7%+29.1%
Debt / equity0.010.110.160.000.200.720.60
Long-term debt / equity0.000.060.090.00-8,210.210.340.22
Interest cover0.682.919.622.186.747.3914.87
Efficiency & per share
Fixed asset turnover2.062.012.052.652.732.703.31
Inventory turnover6.616.095.095.336.036.045.27
Debtors turnover4.083.943.103.153.713.983.82
EPS (₹)44.7319.4911.8422.8719.7517.1426.16
Dividend per share (₹)2.501.503.003.003.000.000.00
Book value per share (₹)203.78160.21183.05161.04142.1652.05102.84

Investments & Acquisitions by Ami organics

Ami organics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Baba Fine Chemicals.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Manufacturer of speciality chemicals
babafinechemicals.comNoida, India2016Apr 2023$8.31M
Premium access

Complete acquisition details for Ami organics

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Ami organics

3 dated milestones of Ami organics across 16 years, from founding to its latest funding, stage changes and deals.

  1. Founded Ami organics is founded.
  2. IPO Lists on the stock exchange (IPO).
  3. Acquisition Acquires Baba Fine Chemicals.

Competitors of Ami organics

Ami organics has 3 listed competitors in our database, 2 of them funded. They include Viyash, Inventys and Blue Jet Healthcare.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
viyash.com2019Hyderabad, India$120.02M277
APIs and intermediates are manufactured by Viyash as a CDMO.
inventys.in2005Mumbai, India$64.34M219
Actives, advanced intermediates, and specialty chemicals are custom manufactured.
bluejethealthcare.com1969Mumbai, India476
CDMO focused on manufacturing, supplier, and development of intermediates & APIs
Premium access

Detailed competitors of Ami organics

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Ami organics

Websites that share an audience with Ami organics (amiorganics.com).

Similar websites

Websites whose visitors overlap most with Ami organics. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
aartipharmalabs.com
100%
5.5K#3,693,630View details
anantrajlimited.com
88%
11.8K#2,145,945View details

Top companies in Biopharma Outsourcing & Drug Delivery

3 companies that operate in the same segment as Ami organics (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Developer of integrated contract research development and manufacturing services
2007Bengaluru, Karnataka, IndiaUSD 35.74 MUSD 226.38 M2,062
Pharmaceutical and biotechnology company
2005Hyderabad, Telangana, IndiaUSD 229.73 MUSD 726.15 M548
India's leading healthcare products distribution platform
2018Mumbai, Maharashtra, IndiaUSD 59.67 MUSD 702.49 M557
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Ami Organics

ACUTAAS: Q2 SL NET PROFIT 1.34B RUPEES VS 730M (YOY)
Exchange Update • 24 days ago
ACUTAAS: Q2 EBITDA 1.83B RUPEES VS 966M (YOY); Q2 EBITDA MARGIN 42.34% VS 31.65% (YOY)
Exchange Update • 24 days ago
ACUTAAS: Q2 REVENUE 4.3B RUPEES VS 3.1B (YOY)
Exchange Update • 24 days ago
ACUTAAS: Increases FY27 Revenue Growth Forecast From 25% To About 30% And Raises EBITDA Margin Guidance To A Range Of 38-40%.
Exchange Update • 24 days ago
Premium access

Complete news archive for Ami organics

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Ami organics

Ami organics was founded in 2007.

Ami organics is headquartered in Surat, India. It is registered at Surat, Gujarat, India.

Ami organics has 244 employees.

The primary company behind Ami organics, Acutaas Chemicals Limited, reported revenue of ₹1,381 Cr for FY 2026, up 33% year on year.

Founded in 2007 and based in Surat, India, Ami Organics operates in the pharmaceutical sector. Advanced intermediates for APIs and new chemical entities are produced, with clinical and commercial services provided. Certifications held include GMP, ISO 9001:2008, ISO 14001:2004, OHSAS 18001:2007, and SA 8000:2008. Memberships are maintained with Common Effluent Treatment Plant and Toxic Solid Disposal Site facilities.

Ami organics's top competitors include Inventys, Viyash and Blue Jet Healthcare.

Ami organics offers Pharmaceutical Intermediates, Speciality Chemicals, Make to Order Products, and Paraben Formulations.

Yes, Ami organics is publicly traded on NSE under the ticker symbol ACUTAAS.

Ami organics has made 1 acquisition, including Baba Fine Chemicals.

Ami organics is associated with 2 legal entities: Acutaas Chemicals Limited, Ami Procure Private Limited.

The legal entities of Ami organics currently have 11 directors, including Richa Manoj Goyal, Nareshkumar Ramjibhai Patel, Girikrishna Maniar and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available